135 related articles for article (PubMed ID: 8105997)
1. Nipradilol, a new beta-blocker with vasodilatory properties, in experimental portal hypertension: a comparative haemodynamic study with propranolol.
Um S; Nishida O; Tokubayashi M; Kimura F; Kita T
J Gastroenterol Hepatol; 1993; 8(5):414-9. PubMed ID: 8105997
[TBL] [Abstract][Full Text] [Related]
2. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol.
Aramaki T; Sekiyama T; Katsuta Y; Kurokawa H; Komeichi H; Tsutsui H; Terada H; Ohsuga M; Satomura K; Okumura H
J Hepatol; 1992 May; 15(1-2):48-53. PubMed ID: 1354676
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic effects of nipradilol, a new beta-adrenergic antagonist combined with a nitroxy base, in rats with intra- or extra-hepatic portal hypertension.
Ohsuga M; Cailmail S; Lebrec D
J Hepatol; 1993 Feb; 17(2):236-40. PubMed ID: 8095275
[TBL] [Abstract][Full Text] [Related]
4. Effect of selective blockade of beta 2-adrenergic receptors on portal and systemic hemodynamics in a portal hypertensive rat model.
Kroeger RJ; Groszmann RJ
Gastroenterology; 1985 Apr; 88(4):896-900. PubMed ID: 2857673
[TBL] [Abstract][Full Text] [Related]
5. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of nipradilol, a beta-adrenoceptor blocker with vasodilating properties.
Fujii M; Shirasawa Y; Kondo S; Sawanobori K; Nakamura M
Jpn Heart J; 1986 Mar; 27(2):233-50. PubMed ID: 2873263
[TBL] [Abstract][Full Text] [Related]
7. Systemic and splanchnic hemodynamics following hemorrhage and volume restitution with Haemaccel in portal hypertensive rats: the effect of propranolol.
Hilzenrat N; Arish A; Yaari A; Sikuler E
J Gastroenterol Hepatol; 2001 Jul; 16(7):796-800. PubMed ID: 11446889
[TBL] [Abstract][Full Text] [Related]
8. Haemodynamic effects of combined treatment with molsidomine and propranolol on portal hypertension in conscious and unrestrained cirrhotic rats.
Hori N; Okanoue T; Sawa Y; Mori T; Kashima K
J Gastroenterol Hepatol; 1996 Oct; 11(10):985-92. PubMed ID: 8912139
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic effects of eight-day octreotide and propranolol administration in portal hypertensive rats.
Huang YT; Cheng YR; Lin HC; Hou MC; Lee SD; Hong CY
Dig Dis Sci; 1998 Feb; 43(2):358-64. PubMed ID: 9512131
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new beta-blocker with nitrovasodilating properties in patients with liver cirrhosis.
Sugano S; Kawafune T; Suzuki T; Kubota M; Okajima T; Sumino Y; Akita H
Am J Gastroenterol; 1995 May; 90(5):788-93. PubMed ID: 7733089
[TBL] [Abstract][Full Text] [Related]
11. Effects of terlipressin on hemodynamics and oxygen content in conscious portal vein stenosed and cirrhotic rats receiving propranolol.
Lebrec D; Moreau R; Cailmail S; Sogni P; Oberti F; Hadengue A
J Hepatol; 1993 Jan; 17(1):102-7. PubMed ID: 8445208
[TBL] [Abstract][Full Text] [Related]
12. Effects of alpha 1 and beta-adrenergic antagonists and 5-hydroxytryptamine receptor antagonist on portal-systemic collateral vascular resistance in conscious rats with portal hypertension.
Koshy A; Sekiyama T; Hadengue A; Cerini R; Braillon A; Lebrec D
J Gastroenterol Hepatol; 1992; 7(5):449-54. PubMed ID: 1391726
[TBL] [Abstract][Full Text] [Related]
13. The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model.
Kroeger RJ; Groszmann RJ
Hepatology; 1985; 5(3):425-30. PubMed ID: 3922868
[TBL] [Abstract][Full Text] [Related]
14. Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study.
Hobolth L; Bendtsen F; Hansen EF; Møller S
Dig Liver Dis; 2014 Mar; 46(3):251-6. PubMed ID: 24290869
[TBL] [Abstract][Full Text] [Related]
15. Haemodynamic effects of octreotide in portal hypertensive rats receiving propranolol.
Moreau R; Cailmail S; Gadano A; Valla D; Lebrec D
Aliment Pharmacol Ther; 1997 Aug; 11(4):775-9. PubMed ID: 9305488
[TBL] [Abstract][Full Text] [Related]
16. Participation of the vasodilating property of nipradilol in improving ischemic derangement of myocardial energy metabolism.
Higuchi M
J Cardiovasc Pharmacol; 1989 Jul; 14(1):157-65. PubMed ID: 2475707
[TBL] [Abstract][Full Text] [Related]
17. Propranolol decreases portal pressure without changing portocollateral resistance in cirrhotic rats.
Pizcueta MP; de Lacy AM; Kravetz D; Bosch J; Rodés J
Hepatology; 1989 Dec; 10(6):953-7. PubMed ID: 2583690
[TBL] [Abstract][Full Text] [Related]
18. Discrepancy between portal pressure and systemic hemodynamic changes after incremental doses of propranolol in awake portal hypertensive rats.
Koshy A; Girod C; Lee SS; Hadengue A; Cerini R; Lebrec D
Hepatology; 1989 Feb; 9(2):269-73. PubMed ID: 2912829
[TBL] [Abstract][Full Text] [Related]
19. A nitric oxide-generating beta-blocking agent prevents renal injury in the rat remnant kidney model. Comparative study of two beta-blocking drugs, nipradilol and propranolol.
Takamitsu Y; Nakanishi T; Nishihara F; Hasuike Y; Izumi M; Inoue T; Hiraoka K; Itahana R; Miyagawa K
Nephron Physiol; 2003; 93(2):p42-50. PubMed ID: 12629270
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.
Schepis F; Vukotic R; Berzigotti A; Carrión JA; Forns X; Abraldes JG; García-Valdecasas JC; Navasa M; García-Pagán JC; Bosch J
Liver Transpl; 2013 Apr; 19(4):450-6. PubMed ID: 23408436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
